Improved Stability of a Model IgG3 by DoE-Based Evaluation of Buffer Formulations
- Food and Drug Administration (FDA), Silver Spring, MD (United States). Center for Drug Evaluation and Research (CDER), Office of Pharmaceutical Quality's (OPQ) Division II
- Food and Drug Administration (FDA), Silver Spring, MD (United States). Center for Drug Evaluation and Research (CDER), Office of Pharmaceutical Quality's (OPQ) Division of Product Quality Research, Office of Testing
- Food and Drug Administration (FDA), Silver Spring, MD (United States). Center for Drug Evaluation and Research (CDER), Office of Pharmaceutical Quality's (OPQ) Division II
- Food and Drug Administration (FDA), Silver Spring, MD (United States). Center for Drug Evaluation and Research (CDER), Office of Pharmaceutical Quality's (OPQ) Division of Pharmaceutical Analysis, Office of Testing and Research
Formulating appropriate storage conditions for biopharmaceutical proteins is essential for ensuring their stability and thereby their purity, potency, and safety over their shelf-life. Using a model murine IgG3 produced in a bioreactor system, multiple formulation compositions were systematically explored in a DoE design to optimize the stability of a challenging antibody formulation worst case. The stability of the antibody in each buffer formulation was assessed by UV/VIS absorbance at 280 nm and 410 nm and size exclusion high performance liquid chromatography (SEC) to determine overall solubility, opalescence, and aggregate formation, respectively. Upon preliminary testing, acetate was eliminated as a potential storage buffer due to significant visible precipitate formation. An additional 24full factorial DoE was performed that combined the stabilizing effect of arginine with the buffering capacity of histidine. From this final DoE, an optimized formulation of 200 mM arginine, 50 mM histidine, and 100 mM NaCl at a pH of 6.5 was identified to substantially improve stability under long-term storage conditions and after multiple freeze/thaw cycles. Therefore, our data highlights the power of DoE based formulation screening approaches even for challenging monoclonal antibody molecules.
- Research Organization:
- Oak Ridge Institute for Science and Education (ORISE), Oak Ridge, TN (United States)
- Sponsoring Organization:
- USDOE Office of Science (SC); US Food and Drug Administration (FDA)
- Grant/Contract Number:
- CDER-Grant-No.1500
- OSTI ID:
- 1376192
- Journal Information:
- BioMed Research International, Vol. 2016; ISSN 2314-6133
- Publisher:
- HindawiCopyright Statement
- Country of Publication:
- United States
- Language:
- English
Web of Science
Exploring the linkage between cell culture process parameters and downstream processing utilizing a plackett-burman design for a model monoclonal antibody
|
journal | November 2016 |
Overview of Antibody Drug Delivery
|
journal | July 2018 |
Similar Records
Chemical degradation of /sup 3/H-labeled substance P in tris buffer solution
Strong antitumor activities of IgG3 antibodies to a human melanoma-associated ganglioside